Insider Buying: Profound Medical (TSE:PRN) Insider Buys 13,908 Shares of Stock

Profound Medical Corp. (TSE:PRN) insider Thomas Michael Tamberrino bought 13,908 shares of the stock in a transaction on Tuesday, December 23rd. The stock was purchased at an average price of C$9.91 per share, with a total value of C$137,828.28. Following the completion of the acquisition, the insider directly owned 39,241 shares in the company, valued at approximately C$388,878.31. This trade represents a 54.90% increase in their position.

Profound Medical Stock Up 0.7%

Shares of Profound Medical stock traded up C$0.07 during trading on Friday, hitting C$10.78. 30,209 shares of the stock traded hands, compared to its average volume of 20,024. Profound Medical Corp. has a 52-week low of C$5.23 and a 52-week high of C$12.40. The company has a current ratio of 6.12, a quick ratio of 14.98 and a debt-to-equity ratio of 20.05. The firm has a market cap of C$391.24 million, a P/E ratio of -8.17 and a beta of 1.19. The stock’s fifty day simple moving average is C$10.11 and its 200 day simple moving average is C$8.34.

Profound Medical (TSE:PRN) last released its quarterly earnings results on Thursday, November 13th. The company reported C$0.26 earnings per share for the quarter. The business had revenue of C$7.36 million for the quarter. Profound Medical had a negative net margin of 349.41% and a negative return on equity of 85.22%. On average, equities analysts predict that Profound Medical Corp. will post -1.9000001 earnings per share for the current fiscal year.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.